Active Stocks
Mon Apr 15 2024 15:59:36
  1. Tata Steel share price
  2. 160.90 -1.59%
  1. ITC share price
  2. 425.90 -0.98%
  1. State Bank Of India share price
  2. 757.75 -1.17%
  1. ICICI Bank share price
  2. 1,078.80 -2.30%
  1. NTPC share price
  2. 361.35 -0.08%
Business News/ Companies / Complex generics, proprietary products to drive growth: Dr. Reddy’s Laboratories
BackBack

Complex generics, proprietary products to drive growth: Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories is creating a branded generics platform in North America and expanding biologics play in Russia and emerging markets

Photo: Hindustan TimesPremium
Photo: Hindustan Times

New Delhi: Dr. Reddy’s Laboratories Ltd expects complex generics, proprietary products, including creation of branded generics platform in the US, to be the main drivers of its growth going forward.

“Our growth, going forward, will be driven by the attractive pipeline of complex generics as well as our new proprietary products," Dr Reddy’s Laboratories chairman K. Satish Reddy said in a message in the company’s latest annual report.

The company will leverage these across the markets we operate in, together with increasing our OTC (over-the-counter) portfolio, he added.

Highlighting the road map the company is taking for expansion, Reddy said, “We are creating a branded generics platform in North America and expanding our biologics play in Russia, CIS (Commonwealth of Independent States) and other emerging markets".

The outlook for the API (active pharmaceutical ingredient) business is also positive, he added. A branded generic is a drug that is a bio-equivalent to the original product, but is now marketed under another company’s brand name.

During fiscal 2016, the company’s revenues from North America for generics grew 19% to 7,540 crore. “The sustained performance of our injectables franchise and market share gains in key molecules were the main reason," Reddy said.

Dr. Reddy’s Laboratories had posted a consolidated net income from sales and services of 15,470.8 crore for 2015-16. It was 14,818.9 crore in the previous fiscal. About other global markets, Reddy, “It is difficult to assess the probable situation in Venezuela and Russia in the near future."

In case of Venezuela, the company has decided to supply medicines only against letters of credit or pre-payment, he added. “We are cautiously optimistic about Russia, given that there is a gradual recovery in the crude prices, and its direct impact on the rouble," he added.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 17 Jul 2016, 10:21 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App